These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12562444)

  • 1. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
    Micklewright R; Lane S; Linley W; McQuade C; Thompson F; Maskrey N
    Aliment Pharmacol Ther; 2003 Feb; 17(3):321-32. PubMed ID: 12562444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
    Mamdani M; Rochon PA; Juurlink DN; Kopp A; Anderson GM; Naglie G; Austin PC; Laupacis A
    BMJ; 2002 Sep; 325(7365):624. PubMed ID: 12242172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSAIDs: gastroprotection or selective COX-2 inhibitor?
    Dickman A; Ellershaw J
    Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase inhibition: between the devil and the deep blue sea.
    Hawkey CJ
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III25-30. PubMed ID: 11953329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
    MacDonald TM; Morant SV; Goldstein JL; Burke TA; Pettitt D
    Gut; 2003 Sep; 52(9):1265-70. PubMed ID: 12912856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.
    Buttgereit F; Burmester GR; Simon LS
    Am J Med; 2001 Feb; 110 Suppl 3A():13S-9S. PubMed ID: 11173045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 15. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
    Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
    BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
    You JH; Lee KK; Chan TY; Lau WH; Chan FK
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs].
    Pedrós C; Cereza G; Laporte JR
    Med Clin (Barc); 2002 Mar; 118(11):415-7. PubMed ID: 11943104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wallace JL
    Am J Med; 1999 Dec; 107(6A):11S-16S; discussion 16S-17S. PubMed ID: 10628589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.